Navigation Links
US Peripheral Vascular Device Market to Grow Strongly to $3.3 Billion by 2017
Date:1/23/2013

TORONTO, Jan. 23, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, increasing awareness and diagnosis of peripheral vascular disease (PVD) along with the introduction of improved next-generation devices will lead the United States peripheral vascular (PV) device market to grow strongly to reach $3.3 billion by 2017.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

Lower extremity treatment will grow substantially, as physicians and device manufacturers continue to focus on the prevention of limb amputation. A variety of recent and upcoming device launches, including drug eluting stents (DES) and drug-coated balloons (DCB), as well as improvements in lower-extremity stents will provide physicians with more options for treating lower extremity peripheral artery disease (PAD).

Growth in the femoral-popliteal (fem-pop) indication will be particularly strong. Historically, concerns about stent fractures have restrained their use, but next-generation devices offer improved flexibility and strength to address this issue. For example, Covidien recently released its Protege EverFlex and Flexible Stenting Solutions released its FlexStent, while IDEV Technologies is anticipated to receive FDA approval for use of the SUPERA VERITAS stent in the fem-pop arteries before 2015.

Furthermore, continued adoption of and physician familiarity with chronic total occlusion (CTO) devices will allow for endovascular treatment of increasingly challenging lesions in these indications, driving overall procedure volumes. In addition to the large players, including Boston Scientific, C. R. Bard, Cordis, Covidien, and Medtronic, this segment has attracted a number of niche competitors such as Avinger, Baylis Medical, and Spectranetics; these companies will be likely acquisition targets for larger competitors looking to expand their lower-extremity PV offerings.

"Aortic stent grafts will be the strongest growing peripheral vascular device segment, spurred by continual device improvement efforts by manufacturers," said MRG Analyst Louise Murphy . "A number of new manufacturers have begun to enter the US market, based on its favorable climate and the need for niche devices and innovations."

Smaller new competitors in the abdominal aortic stent graft segment include Endologix, Aptus Endosystems and TriVascular, with Lombard Medical and Bolton Medical expected to enter the market before 2017. Device innovations such as fenestrated grafts, low-profile devices and improved fixation mechanisms will help differentiate competitors and drive market growth.

Millennium Research Group's US Markets for Peripheral Vascular Devices report includes unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for peripheral vascular (PV) stents, percutaneous transluminal angioplasty (PTA) balloon catheters, chronic total occlusion (CTO) crossing devices, embolic protection devices (EPD), aortic stent grafts, synthetic surgical grafts, and PV accessory devices sold in the United States.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Peripheral Vascular Devices Market to 2018 - Increasing Demand for Minimally Invasive Endovascular Procedures Presents Growth Opportunities for Manufacturers
2. Spinifex Announces Start of Phase 2 Proof-of-Concept Trial of EMA401 in Chemotherapy-Induced Peripheral Neuropathy
3. Anesthesia Equipment and Associated Peripherals: Advanced, Patient-Friendly Devices Will Sustain Market Growth in Europe, States Frost & Sullivan
4. Peripheral Vascular Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
5. Global Peripheral Vascular Devices Market 2011-2015
6. Brazil Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others
7. North America Cardiovascular Devices Market Outlook to 2018 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology Prosthetic Heart Valves and Others
8. European Markets for Peripheral Vascular Devices 2012
9. European Market for Peripheral Vascular Devices
10. Frost & Sullivan to Host Complimentary Web Conference: Concerns and Solutions for the Anaesthesia Equipment and Associated Peripherals Market
11. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
(Date:6/23/2016)... , June 23, 2016 ... but it continues to present great opportunities to investors. ... for today: Intrexon Corp. (NYSE: XON ), ... Pharmaceuticals Inc. (NASDAQ: ARNA ), and Regeneron ... about these stocks and receive your complimentary trade alerts ...
(Date:6/23/2016)... 23, 2016 Leading BioSciences Inc., a ... conditions resulting from a breakdown of the mucosal ... Greg Doyle as chief executive officer. Mr. ... management team and board of directors, previously served ... He will provide continued leadership and strategic direction ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):